Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: Design and mechanism of action

Current Pharmaceutical Design

Volumn 14, Issue 22, 2008, Pages 2128-2139

  Zimmerman, Tahl ^a   Blanco, Francisco J ^a  

^a CIC BIOGUNE   (Spain)

Author keywords

Allosteric inhibitors; Cell adhesion; ICAM 1; Inhibitors; Integrin; LFA 1; Protein protein interaction

Indexed keywords

1,4 DIAZEPANE 2 ONE DERIVATIVE; 1,4 DIAZEPANE 2,5 DIONE DERIVATIVE; ANTIINFLAMMATORY AGENT; AROMATIC AMIDE; BIRT 377; COMPACTIN; HYDANTOIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IC 487475; INTERCELLULAR ADHESION MOLECULE 1; LFA 703; LFA 878; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 INHIBITOR; MEVINOLIN; PEPTIDE DERIVATIVE; PRAVASTATIN; PROTEIN INHIBITOR; PYRROLIDINE DERIVATIVE; SIMVASTATIN; UNCLASSIFIED DRUG; XVA 143;

ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CELL ADHESION; CELL SURFACE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; INFLAMMATORY DISEASE; LUNG CANCER; NEOPLASM; NONHUMAN; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

CELL ADHESION; DRUG DESIGN; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; PROTEIN BINDING;

EID: 52949113847     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785740225     Document Type: Review

References (70)

1. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
2. Humphries MJ, McEwan PA, Barton SJ, Buckley PA, Bella J, Mould AP. Integrin structure: heady advances in ligand binding, but activation still makes the knees wobble. Trends Biochem Sci 2003; 28: 313-20.
3. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, et al. Crystal structure of the extracellular segment of integrin αVβ3. Science 2001; 294: 339-45.
4. Gahmberg CG, Tolvanen M, Kotovuori P. Leukocyte adhesion - structure and function of human leukocyte β2-integrins and their cellular ligands. Eur J Biochem 1997; 245: 215-32.
5. Qu A, Leahy DJ. Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, α L β 2) integrin. Proc Natl Acad Sci USA 1995; 92: 10277-81.
6. Shimaoka M, Lu C, Palframan RT, von Andrian UH, McCormack A, Takagi J, et al. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin αL I domains with high affinity and antagonist activity in vivo. Proc Natl Acad Sci USA 2001; 98: 6009-14.
7. Shimaoka M, Xiao T, Liu JH, Yang Y, Dong Y, Jun CD, et al. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shiffing pathway for integrin regulation. Cell 2003; 112: 99-111.
8. Dransfield I, Cabanas C, Craig A, Hogg N. Divalent cation regulation of the function of the leukocyte integrin LFA-1. J Cell Biol 1992; 116: 219-26.
9. Labadia ME, Jeanfavre DD, Caviness GO, Morelock MM. Molecular regulation of the interaction between leukocyte function-associated antigen-1 and soluble ICAM-1 by divalent metal cations. J Immunol 1998; 161: 836-42.
10. Griggs DW, Schmidt CM, Carron CP. Characteristics of cation binding to the I domains of LFA-1 and MAC-1. The LFA-1 I domain contains a Ca2+-binding site. J Biol Chem 1998; 273: 22113-9.
11. San Sebastian E, Mercero JM, Stote RH, Dejaegere A, Cossio FP, Lopez X. On the affinity regulation of the metal-ion-dependent adhesion sites in integrins. J Am Chem Soc 2006; 128: 3554-63.
12. Nishida N, Xie C, Shimaoka M, Cheng Y, Walz T, Springer TA. Activation of leukocyte β2 integrins by conversion from bent to extended conformations. Immunity 2006; 25: 583-94.
13. Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002; 110: 599-11.
14. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007; 25: 619-47.
15. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin α2β1. Cell 2000; 101: 47-56.
16. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
17. Luo BH, Takagi J, Springer TA. Locking the β3 integrin I-like domain into high and low affinity conformations with disulfides. J Biol Chem 2004; 279: 10215-21.
18. Yang W, Shimaoka M, Salas A, Takagi J, Springer TA. Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring. Proc Natl Acad Sci USA 2004; 101: 2906-11.
19. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002; 22: 146-67.
20. Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. J Leukoc Biol 2005; 77: 129-40.
21. Roossien FF, de Rijk D, Bikker A, Roos E. Involvement of LFA-1 in lymphoma invasion and metastasis demonstrated with LFA-l-deficient mutants. J Cell Biol 1989; 108: 1979-85.
22. Gulubova MV. Expression of cell adhesion molecules, their ligands and tumour necrosis factor α in the liver of patients with metastatic gastrointestinal carcinomas. Histochem J 2002; 34: 67-77.
23. Wang HH, McIntosh AR, Hasinoff BB, MacNeil B, Rector E, Nance DM, et al. Regulation of B16F1 melanoma cell metastasis by inducible functions of the hepatic microvasculature. Eur J Cancer 2002; 38: 1261-70.
24. Soede RD, Zeelenberg IS, Wijnands YM, Kamp M, Roos E. Stromal cell-derived factor-1-induced LFA-1 activation during in vivo migration of T cell hybridoma cells requires Gq/11, RhoA, and myosin, as well as Gi and Cdc42. J Immunol 2001; 166: 4293-301.
25. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
26. Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 2006; 46: 10-20.
27. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005; 19: 165-77.
28. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
29. Liu G, Huth JR, Olejniczak ET, Mendoza R, DeVries P, Leitza S, et al. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J Med Chem 2001; 44: 1202-10.
30. Kelly TA, Jeanfavre DD, McNeil DW, Woska JR Jr, Reilly PL, Mainolfi EA, et al. Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J Immunol 1999; 163: 5173-7.
31. Shimaoka M, Salas A, Yang W, Weitz-Schmidt G, Springer TA. Small molecule integrin antagonists that bind to the β2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 2003; 19: 391-402.
32. Huth JR, Olejniczak ET, Mendoza R, Liang H, Harris EA, Lupher ML Jr, et al. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc Natl Acad Sci USA 2000; 97: 5231-6.
33. Knorr R, Dustin ML. The lymphocyte function-associated antigen 1 I domain is a transient binding module for intercellular adhesion molecule (ICAM)-1 and ICAM-3 in hydrodynamic flow. J Exp Med 1997; 186: 719-30.
34. Astrof NS, Salas A, Shimaoka M, Chen J, Springer TA. Importance of force linkage in mechanochemistry of adhesion receptors. Biochemistry 2006; 45: 15020-8.
35. Salas A, Shimaoka M, Chen S, Carman CV, Springer T. Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin lymphocyte function-associated antigen-1. J Biol Chem 2002; 277: 50255-62.
36. Nam K, Maiorov V, Feuston B, Kearsley S. Dynamic control of allosteric antagonism of leukocyte function antigen-1 and intercellular adhesion molecule-1 interaction. Proteins 2006; 64: 376-84.
37. Lu C, Shimaoka M, Zang Q, Takagi J, Springer TA. Locking in alternate conformations of the integrin αLβ2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci USA 2001; 98: 2393-8.
38. Lu C, Shimaoka M, Ferzly M, Oxvig C, Takagi J, Springer TA. An isolated, surface-expressed I domain of the integrin αLβ2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc Natl Acad Sci USA 2001; 98: 2387-92.
39. Larson RS, Davis T, Bologa C, Semenuk G, Vijayan S, Li Y, et al. Dissociation of I domain and global conformational changes in LFA-1: refinement of small molecule-I domain structure-activity relationships. Biochemistry 2005; 44: 4322-31.
40. Kallen J, Welzenbach K, Ramage P, Geyl D, Kriwacki R, Legge G, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 1999; 292: 1-9.
41. Sarantos MR, Raychaudhuri S, Lum AF, Staunton DE, Simon SI. Leukocyte function-associated antigen 1-mediated adhesion stability is dynamically regulated through affinity and valency during bond formation with intercellular adhesion molecule-1. J Biol Chem 2005; 280: 28290-8.
42. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995; 76: 21A-28A.
43. Weitz-Schmidt G, Welzenbach K, Dawson J, Kallen J. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J Biol Chem 2004; 279: 46764-71.
44. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett 2008; 260: 11-9.
45. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208-17.
46. Liu G, Link JT, Pei Z, Reilly EB, Leitza S, Nguyen B, et al. Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead. J Med Chem 2000; 43: 4025-40.
47. Winn M, Reilly EB, Liu G, Huth JR, Jae HS, Freeman J, et al. Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 4. Structure-activity relationship of substituents on the benzene ring of the cinnamide. J Med Chem 2001; 44: 4393-403.
48. Pei Z, Xin Z, Liu G, Li Y, Reilly EB, Lubbers NL, et al. Discovery of potent antagonists of leukocyte function-associated antigen-1/ intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides. J Med Chem 2001; 44: 2913-20.
49. Crump MP, Ceska TA, Spyracopoulos L, Henry A, Archibald SC, Alexander R, et al. Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry. Biochemistry 2004; 43: 2394-404.
50. Green CE, Schaff UY, Sarantos MR, Lum AF, Staunton DE, Simon SI. Dynamic shifts in LFA-1 affinity regulate neutrophil rolling, arrest, and transmigration on inflamed endothelium. Blood 2006; 107: 2101-11.
51. Last-Barney K, Davidson W, Cardozo M, Frye LL, Grygon CA, Hopkins JL, et al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein-protein interaction. J Am Chem Soc 2001; 123: 5643-50.
52. Woska JR Jr, Shih D, Taqueti VR, Hogg N, Kelly TA, Kishimoto TK. A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function. J Leukoc Biol 2001; 70: 329-34.
53. Wu JP, Emeigh J, Gao DA, Goldberg DR, Kuzmich D, Miao C, et al. Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-α]imidazol-2-one derivatives. J Med Chem 2004; 47: 5356-66.
54. Dodd DS, Sheriff S, Chang CJ, Stetsko DK, Phillips LM, Zhang Y, et al. Design of LFA-1 antagonists based on a 2,3-dihydro-1Hpyrrolizin-5(7aH)-one scaffold. Bioorg Med Chem Lett 2007; 17: 1908-11.
55. Wattanasin S, Albert R, Ehrhardt C, Roche D, Sabio M, Hommel U, et al. 1,4-Diazepane-2-ones as novel inhibitors of LFA-1. Bioorg Med Chem Lett 2003; 13: 499-502.
56. Wattanasin S, Kallen J, Myers S, Guo Q, Sabio M, Ehrhardt C, et al. 1,4-Diazepane-2,5-diones as novel inhibitors of LFA-1. Bioorg Med Chem Lett 2005; 15: 1217-20.
57. Potin D, Launay M, Monatlik F, Malabre P, Fabreguettes M, Fouquet A, et al. Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo- 1,3,7-triazaspiro [4.4]non-7-yl-methyl-3-thiophenecarboxylic acid (BMS-587101)-a small molecule antagonist of leukocyte function associated antigen-1. J Med Chem 2006; 49: 6946-9.
58. Zubia A, Mendoza L, Vivanco S, Aldaba E, Carrascal T, Lecea B, et al. Application of Stereocontrolled Stepwise [3+2] Cycloadditions to the Preparation of Inhibitors of α (4) β1)-Integrin-Mediated Hepatic Melanoma Metastasis. Angew Chem Int Ed Engl 2005; 44: 2903-07.
59. Tibbetts SA, Jois SD, Siahaan TJ, Benedict SH, Chan MA. Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function. Peptides 2000; 21: 1161-7.
60. Anderson ME, Tejo BA, Yakovleva T, Siahaan TJ. Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion. Chem Biol Drug Des 2006; 68: 20-8.
61. Zimmerman T, Oyarzabal J, Sebastian ES, Majumdar S, Tejo BA, Siahaan TJ, et al. ICAM-1 peptide inhibitors of T-cell adhesion bind to the allosteric site of LFA-1. An NMR characterization. Chem Biol Drug Des 2007; 70: 347-53.
62. Gadek TR, Burdick DJ, McDowell RS, Stanley MS, Marsters JC Jr, Paris KJ, et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 2002; 295: 1086-9.
63. Welzenbach K, Hommel U, Weitz-Schmidt G. Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. Molecular insights into integrin inhibition. J Biol Chem 2002; 277: 10590-8.
64. Keating SM, Clark KR, Stefanich LD, Arellano F, Edwards CP, Bodary SC, et al. Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the α1 subunit of lymphocyte function-associated antigen-1. Protein Sci 2006; 15: 290-303.
65. Yang W, Carman CV, Kim M, Salas A, Shimaoka M, Springer TA. A small molecule agonist of an integrin, αLβ2. J Biol Chem 2006; 281: 37904-12.
66. Yin H, Gerlach LO, Miller MW, Moore DT, Liu D, Vilaire G, et al. Arylamide derivatives as allosteric inhibitors of the integrin α2β1/type I collagen interaction. Bioorg Med Chem Lett 2006; 16: 3380-2.
67. Kapyla J, Pentikainen OT, Nyronen T, Nissinen L, Lassander S, Jokinen J, et al. Small molecule designed to target metal binding site in the α2 I domain inhibits integrin function. J Med Chem 2007; 50: 2742-6.
68. Jiang Z. Computational analysis of the interaction between ligand-receptor pairs. Curr Pharm Des 2008; 14(6): 588-92.
69. Robertson JH, Iga AM, Sales KM, Winslet MC, Seifalian AM. Integrins: a method of early intervention in the treatment of colorectal liver metastases. Curr Pharm Des 2008; 14(3): 296-305.
70. Vannini N, Pfeffer U, Lorusso G, Noonan DM, Albini A. Endothelial cell aging and apoptosis in prevention and disease: E-selectin expression and modulation as a model. Curr Pharm Des 2008; 14(3): 221-5.